Australia Liver Diseases Therapeutics Market Report 2022 to 2030

Australia Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Australia Liver Disease Therapeutics market will reach a value of $483 Mn from $277 Mn in 2022, growing at a CAGR of 7.2% during 2022-2030. Liver Disease Therapeutics in Australia is dominated by a few domestic pharmaceutical companies such as Aspen Pharmacare Australia, Mayne Pharma, and Phebra. The Liver Disease Therapeutics market in Australia is segmented into different types of disease and different therapy types. Some of the major factors affecting the Australian Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10AUPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Dr. Vishwa Modhia

Buy Now

Australia Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Australia Liver Disease Therapeutics market will reach a value of $483 Mn from $277 Mn in 2022, growing at a CAGR of 7.2% during 2022-2030.

Australia is a high-income developed country in Oceania bordering the Indian Ocean and the Southern Pacific Ocean NAFLD is growing more widespread in Australia as a result of shifting food patterns and lifestyle variables. According to studies, the prevalence of NAFLD in Australia is between 20 and 25%. Cirrhosis is a common result of chronic liver disease, and it is estimated that 80,000 people in Australia have cirrhosis. Cirrhosis can result in liver failure, malignancy, and death.

According to the latest WHO data published in 2020 Liver Disease Deaths in Australia reached 1,421 or 1.04% of total deaths. The age-adjusted Death Rate is 3.89 per 100,000 population ranks Australia 172^nd in the world. Australia's government spent 10.7% of its GDP on healthcare in 2020.

Australia Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Alcohol-related liver disease is a major issue in Australia, especially among men. Heavy drinking is linked to a higher risk of cirrhosis and liver cancer. Patients with chronic liver disease may also be eligible for a Chronic Disease Management Plan (CDMP) under Medicare, which covers allied health services such as dietitians and physiotherapists. Australia is geographically close to vibrant Asian economies and a member of the RCEP. It also has a high standard of life as a result of immigration, which is fuelling population expansion and ailment prevalence. These aspects could boost Australia's Liver Disease Therapeutics market.

Market Restraints

Treatment of liver disease frequently necessitates access to hepatologists, liver transplant surgery, or interventional radiology. However, in some areas of Australia, these resources may be scarce, resulting in treatment delays or the necessity for patients to travel significant distances to receive care. Australia's economy is still heavily reliant on Chinese expenditure. The differences between Australia's federated states are enormous. These factors may deter new entrants into the Australian Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Mayne Pharma Group: Mayne Pharma Group is an Australian pharmaceutical company that develops and produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Mesalamine
Phebra: Phebra is an Australian pharmaceutical company that produces a variety of therapeutics, including those for liver disease. Its liver disease products include Lactulose and Metronidazole
Sigma Pharmaceuticals: Sigma Pharmaceuticals is an Australian pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Lactulose and Ursodeoxycholic acid
Aspen Pharmacare Australia: Aspen Pharmacare Australia is an Australian subsidiary of Aspen Pharmacare Holdings, a multinational pharmaceutical company that develops and produces a range of therapeutic products, including those for liver disease

Recent Notable Updates

March 2022: Phebra has been granted TGA approval to manufacture critical care medicines for TGA trials. Phebra, a leading Australian pharmaceutical business, is pleased to announce the expansion of its manufacturing licence for its multi-purpose sterile-injectables factory in Lane Cove West, Sydney, with TGA approval to manufacture therapeutic items for clinical studies. Prior to TGA approval, Phebra solely manufactured pharmaceutical medicines for commercial use.

Healthcare Policies and Reimbursement Scenarios

In Australia, the regulation and reimbursement of liver therapeutics are primarily overseen by the Therapeutic Goods Administration (TGA) and the Pharmaceutical Benefits Scheme (PBS), respectively. In terms of reimbursement, the PBS covers the cost of liver therapeutics for patients who meet certain criteria. The reimbursement process is managed by the Department of Health, which determines which therapies are eligible for reimbursement and the conditions under which they will be covered.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.